UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of: July 2025
Commission File Number: 001-38428
PolyPid Ltd.
(Translation of registrant’s name into
English)
18 Hasivim Street
Petach Tikva 495376, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form
40-F
CONTENTS
Attached hereto and incorporated
herein is PolyPid Ltd.’s (the “Company”) press release issued on July 15, 2025, titled “PolyPid Unveils a Long-Acting
GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market.”
The first and the third paragraphs
and the section titled “Forward-looking Statements” in the press release are incorporated by reference into the
Company’s registration statements on Form F-3 (File No. 333-276826,
File No. 333-280658,
File No. 333-281863,
and File No. 333-284376)
and Form S-8 (File No. 333-239517,
File No. 333-271060, File
No. 333-277703 and
File No. 333-280662) filed
with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded
by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit No. |
|
|
| 99.1 |
|
Press release issued by PolyPid Ltd. on July 15, 2025, titled “PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market.” |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
POLYPID LTD. |
| |
|
|
| Date: July 15, 2025 |
By: |
/s/ Dikla Czaczkes Akselbrad |
| |
|
Name |
Dikla Czaczkes Akselbrad |
| |
|
Title: |
Chief Executive Officer |
3
